Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Hester Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Hester Biosciences için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi	45.6%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Hester Biosciences Limited's (NSE:HESTERBIO) CEO Compensation Looks Acceptable To Us And Here's Why

Aug 23

What Hester Biosciences Limited's (NSE:HESTERBIO) 26% Share Price Gain Is Not Telling You

Jul 27

Revenues Working Against Hester Biosciences Limited's (NSE:HESTERBIO) Share Price

Jun 12

Hester Biosciences (NSE:HESTERBIO) Has Announced A Dividend Of ₹10.00

Aug 01

Would Hester Biosciences Limited (NSE:HESTERBIO) Be Valuable To Income Investors?

Mar 03

Did You Miss Hester Biosciences' (NSE:HESTERBIO) Whopping 308% Share Price Gain?

Feb 13

What Is The Ownership Structure Like For Hester Biosciences Limited (NSE:HESTERBIO)?

Jan 26

Who Has Been Buying Hester Biosciences Limited (NSE:HESTERBIO) Shares?

Jan 11

Hester Biosciences Limited's (NSE:HESTERBIO) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Dec 25

Are Hester Biosciences's (NSE:HESTERBIO) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 10

These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

Nov 25

How Does Hester Biosciences Limited (NSE:HESTERBIO) Fare As A Dividend Stock?

Nov 10

If You Had Bought Hester Biosciences (NSE:HESTERBIO) Shares Five Years Ago You'd Have Earned 212% Returns

Oct 26

What Type Of Shareholders Own The Most Number of Hester Biosciences Limited (NSE:HESTERBIO) Shares?

Oct 05

Are Strong Financial Prospects The Force That Is Driving The Momentum In Hester Biosciences Limited's NSE:HESTERBIO) Stock?

Sep 14

These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

Aug 25

How Much Are Hester Biosciences Limited (NSE:HESTERBIO) Insiders Taking Off The Table?

Aug 07

Hester Biosciences Limited (NSE:HESTERBIO) Is Yielding 0.5% - But Is It A Buy?

Jul 07

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Hester Biosciences yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NSEI:HESTERBIO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	3,057	194	N/A	N/A	N/A
3/31/2024	3,112	189	237	481	N/A
12/31/2023	2,992	185	N/A	N/A	N/A
9/30/2023	3,106	257	-52	228	N/A
6/30/2023	3,164	285	N/A	N/A	N/A
3/31/2023	2,782	266	-542	236	N/A
12/31/2022	2,723	298	N/A	N/A	N/A
9/30/2022	2,514	271	-1,404	52	N/A
6/30/2022	2,379	308	N/A	N/A	N/A
3/31/2022	2,466	393	-870	87	N/A
12/31/2021	2,504	413	N/A	N/A	N/A
9/30/2021	2,501	451	219	357	N/A
6/30/2021	2,397	412	N/A	N/A	N/A
3/31/2021	2,177	344	173	581	N/A
12/31/2020	1,989	275	N/A	N/A	N/A
9/30/2020	1,917	267	-385	408	N/A
6/30/2020	1,848	265	N/A	N/A	N/A
3/31/2020	1,878	292	-367	368	N/A
12/31/2019	1,956	396	N/A	N/A	N/A
9/30/2019	1,906	409	128	598	N/A
6/30/2019	1,890	413	N/A	N/A	N/A
3/31/2019	1,842	416	241	467	N/A
3/31/2018	1,373	256	N/A	380	N/A
3/31/2017	1,232	235	N/A	348	N/A
3/31/2016	1,009	192	N/A	188	N/A
3/31/2015	900	136	N/A	198	N/A
3/31/2014	690	95	N/A	94	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: HESTERBIO 'un tahmini kazanç büyümesinin tasarruf oranının ( 6.7% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: HESTERBIO 'un kazançlarının Indian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: HESTERBIO şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: HESTERBIO şirketinin gelirinin Indian pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: HESTERBIO şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: HESTERBIO 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Hester Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased to ₹2,015

Price target increased to ₹2,780

Recent updates

Hester Biosciences Limited's (NSE:HESTERBIO) CEO Compensation Looks Acceptable To Us And Here's Why

Upcoming dividend of ₹6.00 per share

New major risk - Financial position

Full year 2024 earnings released: EPS: ₹22.20 (vs ₹31.30 in FY 2023)

What Hester Biosciences Limited's (NSE:HESTERBIO) 26% Share Price Gain Is Not Telling You

Hester Biosciences Limited, Annual General Meeting, Aug 29, 2024

Hester Biosciences Limited to Report Q1, 2025 Results on Aug 02, 2024

Revenues Working Against Hester Biosciences Limited's (NSE:HESTERBIO) Share Price

Full year 2024 earnings released: EPS: ₹24.88 (vs ₹31.30 in FY 2023)

Hester Biosciences Limited Proposes Dividend for the Financial Year 2023- 24

Hester Biosciences Limited to Report Q4, 2024 Results on May 10, 2024

Investor sentiment improves as stock rises 19%

Hester Biosciences Limited Announces Executive Changes

Third quarter 2024 earnings released: EPS: ₹4.73 (vs ₹14.29 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹4.75 (vs ₹7.77 in 2Q 2023)

Upcoming dividend of ₹8.00 per share at 0.5% yield

Hester Biosciences Limited to Report Q2, 2024 Results on Nov 14, 2023

Hester Biosciences Limited Recommends Dividend for the Financial Year 2022-23, Dividend Payment Date on or After Monday, 25 September 2023

First quarter 2024 earnings released: EPS: ₹7.89 (vs ₹4.19 in 1Q 2023)

Hester Biosciences Limited to Report Q1, 2024 Results on Aug 08, 2023

Hester Biosciences Limited Recommends Dividend for the Financial Year 2022-23

Full year 2023 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Hester Biosciences Limited to Report Q3, 2023 Results on Jan 31, 2023

Now 20% undervalued after recent price drop

Price target decreased to ₹2,015

Second quarter 2023 earnings released: EPS: ₹7.77 (vs ₹13.08 in 2Q 2022)

Hester Biosciences Limited to Report Q2, 2023 Results on Nov 04, 2022

Now 26% undervalued

Now 22% undervalued after recent price drop

Upcoming dividend of ₹10.00 per share

Full year 2022 earnings: EPS and revenues miss analyst expectations

Hester Biosciences Limited to Report Q1, 2023 Results on Aug 10, 2022

Hester Biosciences (NSE:HESTERBIO) Has Announced A Dividend Of ₹10.00

Hester Biosciences Limited, Annual General Meeting, Aug 23, 2022

Hester Biosciences Limited Efforts to Combat the Current Outbreak of Lumpy Skin Disease in Gujarat and Certain Other Parts of India

Now 21% undervalued after recent price drop

Hester Biosciences Limited Recommends Dividend for the Financial Year 2021-22

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to ₹2,780

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS ₹13.08 (vs ₹7.86 in 2Q 2021)

Upcoming dividend of ₹10.00 per share

Full year 2021 earnings released: EPS ₹40.47 (vs ₹34.29 in FY 2020)

Chief Financial Officer Chetas Patel has left the company

Full year 2021 earnings released: EPS ₹40.79 (vs ₹34.29 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Would Hester Biosciences Limited (NSE:HESTERBIO) Be Valuable To Income Investors?

Did You Miss Hester Biosciences' (NSE:HESTERBIO) Whopping 308% Share Price Gain?

Third quarter 2021 earnings released: EPS ₹15.13 (vs ₹14.05 in 3Q 2020)

What Is The Ownership Structure Like For Hester Biosciences Limited (NSE:HESTERBIO)?

New 90-day low: ₹1,655

Hester Biosciences Limited to Report Q3, 2021 Results on Jan 30, 2021

Who Has Been Buying Hester Biosciences Limited (NSE:HESTERBIO) Shares?

Hester Biosciences Limited's (NSE:HESTERBIO) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

New 90-day low: ₹1,683

Are Hester Biosciences's (NSE:HESTERBIO) Statutory Earnings A Good Guide To Its Underlying Profitability?

These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

How Does Hester Biosciences Limited (NSE:HESTERBIO) Fare As A Dividend Stock?

First half earnings released

If You Had Bought Hester Biosciences (NSE:HESTERBIO) Shares Five Years Ago You'd Have Earned 212% Returns

New 90-day high: ₹1,850

What Type Of Shareholders Own The Most Number of Hester Biosciences Limited (NSE:HESTERBIO) Shares?

New 90-day high: ₹1,753

Are Strong Financial Prospects The Force That Is Driving The Momentum In Hester Biosciences Limited's NSE:HESTERBIO) Stock?

These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

New 90-day high - ₹1,558

Upcoming Dividend of ₹6.60 Per Share

How Much Are Hester Biosciences Limited (NSE:HESTERBIO) Insiders Taking Off The Table?

New 90-day high - ₹1,348